Actelion Wins FDA Approval for Lung Disorder Therapy

Actelion won U.S. approval for the lung drug Opsumit, giving the Swiss company a successor to a best-selling medicine that loses patent protection in late 2015. The FDA said it approved Opsumit, also known as macitentan, as a once-daily pill for the treatment of pulmonary arterial hypertension.
Bloomberg